Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.

β-hemoglobinopathies, which include β-thalassemia and sickle cell disease (SCD), comprise a heterogeneous group of disorders of hemoglobin (Hb) synthesis and structure [1]. Around 7% of the world p...